<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Quality assurance is a key issue in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> screening, because effective screening is able to improve primary prevention of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The quality measure may be described in terms: how well the screening test tells who truly has a disease (sensitivity) and who truly does not have a disease (specificity) </plain></SENT>
<SENT sid="2" pm="."><plain>This paper raises concerns about identification of the optimal screening test for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Colonoscopy vs flexible sigmoidoscopy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> screening has been a source of ongoing debate </plain></SENT>
<SENT sid="4" pm="."><plain>A multicentre randomised controlled trial comparing flexible sigmoidoscopy with usual care showed that flexible sigmoidoscopy screening is able to diminish the incidence of distal and proximal <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and also mortality related to the distal <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>However, colonoscopy provides a more complete examination and remains the more sensitive exam than flexible sigmoidoscopy </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, colonoscopy with polypectomy significantly reduces <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> incidence and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-related mortality in the general population </plain></SENT>
<SENT sid="7" pm="."><plain>The article considers the relative merits of both methods and stresses an ethical aspect of patient's involvement in decision-making </plain></SENT>
<SENT sid="8" pm="."><plain>Patients should be informed not only about tests tolerability and risk of endoscopy complications, but also that different screening tests for <z:e sem="disease" ids="C0346627" disease_type="Neoplastic Process" abbrv="">bowel cancer</z:e> have different strength to exclude <z:e sem="disease" ids="C0007102" disease_type="Neoplastic Process" abbrv="">colonic cancer</z:e> and <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>The authorities calculate effectiveness and costs of the screening tests, but patients may not be interested in statistics regarding flexible sigmoidoscopy screening and from an ethical point of view, they have the right to chose colonoscopy, which is able to exclude a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:e sem="disease" ids="C0940937" disease_type="Neoplastic Process" abbrv="">precancerous lesions</z:e> in the whole large bowel </plain></SENT>
</text></document>